Phenylbutyrate Oral Tablet ( DrugBank: Phenylbutyrate )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 15 | Inclusion body myositis | 1 |
15. Inclusion body myositis
Clinical trials : 42 / Drugs : 60 - (DrugBank : 16) / Drug target genes : 12 - Drug target pathways : 123
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04421677 (ClinicalTrials.gov) | August 20, 2020 | 18/5/2020 | Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis | Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis | Inclusion Body Myositis;Sporadic Inclusion Body Myositis | Drug: Phenylbutyrate Oral Tablet | University of Kansas Medical Center | NULL | Active, not recruiting | 18 Years | N/A | All | 10 | Phase 1 | United States |